Immunotherapy

The FDA cleared an investigational new drug application for the combination of AFM24 and SNK-01 in patients with solid tumors that express epidermal growth factor receptor, according to a joint press release from each agent’s manufacturer.

In this video, Debu Tripathy, MD, professor and chair of the department of breast medical oncology at The University of Texas MD Anderson Cancer Center and a HemOnc Today Editorial Board member, discussed immunotherapy updates presented at the 38th Annual Miami Breast Cancer Conference.

Chronic immune-related adverse events appeared more common than previously thought among patients with stage III to stage IV melanoma who received adjuvant anti-PD-1 therapy, according to study results published in JAMA Oncology.

A trial designed to evaluate the addition of relatlimab to nivolumab for untreated metastatic or unresectable melanoma met its primary endpoint of improved PFS, according to topline data released by the agent’s manufacturer.

Chemotherapy did not increase risk for hospitalization or death due to COVID-19 among women with gynecologic cancer, according to results presented at the virtual Society of Gynecologic Oncology Annual Meeting on Women’s Cancer.

The COVID-19 pandemic presents many challenges to health care and, more specifically, cancer care. Patients with lung cancer have high rates of complication due to their underlying disease.

Neoadjuvant combination immunotherapy improved outcomes for patients with operable non-small cell lung cancer, according to results of the randomized phase 2 NEOSTAR trial.

In this video, Kelly K. Hunt, MD, FACS, FSSO, professor and chair of the department of breast surgical oncology at The University of Texas MD Anderson Cancer Center, highlighted updated presentations in immunotherapy at the virtual 38th Annual Miami Breast Cancer Conference.

FDA’s Oncologic Drugs Advisory Committee plans to hold a public meeting April 27-29 to review six indications for cancer drugs granted accelerated approval that subsequently failed to show clinical benefit in confirmatory trials.

Tumor mutational burden predicted immunotherapy response for some, but not all, cancer types, according to study results published in Annals of Oncology.